uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
uniQure N.V. (QURE) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 4.19 M | -102,951,000 | 624.02 M | 831.69 M | 651.85 M |
| 2022 | 102.38 M | -85,120,000 | 228.96 M | 704.96 M | 476.77 M |
| 2021 | 58.77 M | -420,532,000 | 213.4 M | 809.18 M | 628.24 M |
| 2020 | 6.62 M | -173,388,000 | 96.49 M | 340.4 M | 258.91 M |
| 2019 | 947 K | -304,733,000 | 125.57 M | 448.63 M | 384.21 M |